CoChat

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions

Open access
Sharma, Abhinav, Pagidipati, Neha J., Califf, Robert M., McGuire, Darren K., Green, Jennifer B., Demets, Dave, George, Jyothis Thomas, Gerstein, Hertzel C., Hobbs, Todd, Holman, Rury R., Lawson, Francesca C., Leiter, Lawrence A., Pfeffer, Marc A., Reusch, Jane, Riesmeyer, Jeffrey S., Roe, Matthew T., Rosenberg, Yves, Temple, Robert, Wiviott, Stephen, McMurray, John, Granger, Christopher · 2020 · Circulation
Cited by 110

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the US Food and Drug Administration and the Committee for Medicinal Products for Human Use of the European Medicines Agency issued guidance to the pharmaceutical industry in 2008. Glucose-lowering therapies were granted regulatory approval primarily from smaller studies that have demonstrated reductions in glycated hemoglobin concentration. Such studies were overall underpowered and of insufficient duration to show any effect on cardiovascular outcomes. The 2008 guidance aimed to ensure the cardiovascular safety of new glucose-lowering therapies to treat patients with type 2 diabetes mellitus. This resulted in a plethora of new cardiovascular outcome trials, most designed primarily as placebo-controlled noninferiority trials, but with many also powered for superiority. Several of these outcome trials demonstrated cardiovascular benefits of the newer agents, resulting in the first-ever cardiovascular protection indications for glucose-lowering therapies. Determining whether the guidance continues to have value in its current form is critically important as we move forward after the first decade of implementation. In February 2018, a think tank comprising representatives from academia, industry, and regulatory agencies convened to consider the guidance in light of the findings of the completed cardiovascular outcome trials. The group made several recommendations for future regulatory guidance and for cardiovascular outcome trials of glucose-lowering therapies. These recommendations include requiring only the 1.3 noninferiority margin for regulatory approval, conducting trials for longer durations, considering studying glucose-lowering therapies as first-line management of type 2 diabetes mellitus, considering heart failure or kidney outcomes within the primary outcome, considering head-to-head active comparator trials, increasing the diversity of patients enrolled, evaluating strategies to streamline registries and the study of unselected populations, and identifying ways to improve translation of trial results to general practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.119.041022

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 110

Metadata

Authors
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., Lawson, F. C., Leiter, L. A., Pfeffer, M. A., Reusch, J., Riesmeyer, J. S., Roe, M. T., Rosenberg, Y., Temple, R., Wiviott, S., McMurray, J., & Granger, C.
Venue
Circulation
Published
2020-03-10
Volume
141
Issue
10
Pages
843-862
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W3004095885
Cited by
110
References
34
FWCI
9.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. https://app.cochat.ai/papers/10.1161/circulationaha.119.041022
The paper
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., Demets, D., George, J. T., Gerstein, H. C., Hobbs, T., Holman, R. R., Lawson, F. C., Leiter, L. A., Pfeffer, M. A., Reusch, J., Riesmeyer, J. S., Roe, M. T., Rosenberg, Y., Temple, R., Wiviott, S., . . . Granger, C. (2020). Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. https://doi.org/10.1161/circulationaha.119.041022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.